SCHEMBL9320116

SCHEMBL9320116

CN(C)C(=S)Oc1ccc(C=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
CYP2A6 P11509 3/20 0.48
KMT2A Q03164 4/20 0.47
ALDH1A3 P47895 2/20 0.44
RAB9A P51151 1/20 0.44
CYP2A13 Q16696 1/20 0.44
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 2/20 0.40
PARP10 Q53GL7 1/20 0.40
PARP3 Q9Y6F1 1/20 0.40
STS P08842 1/20 0.39
ALDH5A1 P51649 1/20 0.39
ABAT P80404 1/20 0.39
HPGD P15428 1/20 0.38
ALDH3A1 P30838 1/20 0.37
BCHE P06276 1/20 0.37
DRD1 P21728 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13858440 0.81 LMNA (0.35) ALDH1A1CYP2A6KMT2ARAB9ACYP2A13
SCHEMBL8610584 0.80 SRC (0.49) ALDH1A1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL1665873 0.79 RAB9A (0.73) ALDH1A1CYP2A6KMT2AALDH1A3RAB9A
SCHEMBL6553235 0.77 LMNA (0.55) ALDH1A1KMT2ARAB9AKDM4ELMNA
SCHEMBL20473356 0.75 TYR (0.58) ALDH1A1RAB9AMAPT
SCHEMBL5155573 0.75 RAB9A (0.43) ALDH1A1KMT2ARAB9ALMNASMN1; SMN2
SCHEMBL9711102 0.74 MAPT (0.53) ALDH1A1KMT2ARAB9ALMNASMN1; SMN2
SCHEMBL7781426 0.74 MAPT (0.46) ALDH1A1KMT2ARAB9AKDM4ELMNA
SCHEMBL4677215 0.74 ALDH1A1 (0.62) ALDH1A1KDM4ESMN1; SMN2MAPTALDH5A1
SCHEMBL10277064 0.74 CYP1A1 (0.62) KMT2ARAB9AKDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4716685-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-04-01 EP disclosed
US-20260070906-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2026-03-12 US disclosed
US-20260060985-A1 Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof GALECTIN SCIENCES, LLC (US) 2026-03-05 US disclosed
US-12377102-B2 Compounds for the prevention and treatment of medical disorders and uses thereof GALECTIN SCIENCES, LLC (US) 2025-08-05 US disclosed
WO-2024240726-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-11-28 WO disclosed
CN-111032039-B Compounds for the prevention and treatment of medical disorders and uses thereof 卡莱克汀科学有限责任公司 2024-03-26 CN disclosed
US-20230116370-A1 Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof GALECTIN SCIENCES, LLC 2023-04-13 US disclosed
US-11583530-B2 Compounds for the prevention and treatment of medical disorders and uses thereof GALECTIN SCIENCES, LLC (US) 2023-02-21 US disclosed
US-11583530-B2 Compounds for the prevention and treatment of medical disorders and uses thereof GALECTIN SCIENCES, LLC (US) 2023-02-21 US disclosed
US-20200147088-A1 Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof GALECTIN SCIENCES, LLC 2020-05-14 US disclosed
US-20200147088-A1 Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof GALECTIN SCIENCES, LLC 2020-05-14 US disclosed
CN-111032039-A Compounds for the prevention and treatment of medical disorders and uses thereof 卡莱克汀科学有限责任公司 2020-04-17 CN disclosed
EP-0358880-B1 Use of retinoids HOFFMANN LA ROCHE (CH) 1994-01-19 EP disclosed
EP-0358880-A2 Use of retinoids F. HOFFMANN-LA ROCHE AG (CH) 1990-03-21 EP disclosed
EP-0058370-B1 TETRAHYDRONAPHTHALENE AND INDAN COMPOUNDS, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-12-12 EP disclosed
US-4396553-A Tetrahydronaphthalene and indane compounds useful as anti-tumor agents HOFFMANN-LA ROCHE INC. (US) 1983-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060985-A1 Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof LGALS3, LGALS1, LGALS2 ALDH1A1 1833/4885CYP2A6 2282/4885KMT2A 4516/4885
US-20230116370-A1 Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof LGALS1, LGALS2, LGALS3 ALDH1A1 1242/4885CYP2A6 1841/4885KMT2A 4754/4885
US-20260070906-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER TLR1, TLR6, TLR8 ALDH1A1 1320/4885CYP2A6 1747/4885KMT2A 1505/4885
US-20200147088-A1 Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof LGALS1, LGALS2, LGALS3 ALDH1A1 1242/4885CYP2A6 1841/4885KMT2A 4754/4885
US-11583530-B2 Compounds for the prevention and treatment of medical disorders and uses thereof LGALS1, LGALS2, LGALS3 ALDH1A1 1242/4885CYP2A6 1841/4885KMT2A 4754/4885
US-12377102-B2 Compounds for the prevention and treatment of medical disorders and uses thereof LGALS1, LGALS2, LGALS3 ALDH1A1 1242/4885CYP2A6 1841/4885KMT2A 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.